Treatment with Alemtuzumab, which recognizes CD52 on CAR T cells, would eliminate infused CD4 CAR T cells after tumor depletion, thus preventing toxicities associated with CD4+ cell aplasia caused by long-term persistence of CAR T cells. Here, CD4 is linked to neoplasm.